Study explorer (study characteristics and results) method abbreviations

display ongoing studies
Study studied treatmentcontrol treatmentpatientsrisk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Metcovid, 2020
 
NCT04343729
RCTmethylprednisoloneplaceboCOVID 19 hospitalizedsome concern
209/207 inconclusive
  • inconclusive 8 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
RECOVERY dexamethasone, 2020
 
NCT04381936
RCTdexamethasonestandard of careCOVID 19 hospitalizedsome concern
2104/4321 conclusif
  • demonstrated 17 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 10 % increase in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
in an exploratory subgroup analysis there was no benefit among patients who did not require oxygen (1.22 [0.86 to 1.75]; p=0.14)
GLUCOCOVID, 2020OBScorticosteroidscontrolCOVID 19 hospitalizedserious
34/29 suggested
  • suggested 45 % decrease in clinical worsening but with a low degree of certainty due to high risk of bias
Fernández Cruz, 2020OBScorticosteroidsstandard of careCOVID 19 hospitalizedserious
396/67 suggested
  • suggested 66 % decrease in deaths but with a low degree of certainty due to high risk of bias

COVID-19 meta-analysis

Wu, 2020OBScorticosteroidscontrolCOVID-19serious
-/- suggested
  • suggested 62 % decrease in deaths but with a low degree of certainty due to high risk of bias

COVID-19 severe or critically meta-analysis

CAPE-COVID, 2020
 
NCT02517489
RCTHydrocortisoneplaceboCOVID-19 severe or criticallylow
76/73 inconclusive
    no demonstrated benefit a
  • inconclusive 29 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
CODEX (Tomazini), 2020
 
NCT04327401
RCTdexamethasonestandard of careCOVID-19 severe or criticallysome concern
151/148 inconclusive
    no demonstrated benefit a
Edalatifard, 2020
 
IRCT20200404046947N1
RCTmethylprednisolonestandard of careCOVID-19 severe or criticallyhigh
34/34 conclusif
  • demonstrated 71 % decrease in deaths (PE) but with a low degree of certainty due to high risk of bias
REMAP-CAP, fixed 7-day course, 2020
 
NCT02735707
RCTHydrocortisonestandard of careCOVID-19 severe or criticallysome concern
143/108 inconclusive
    no demonstrated benefit a
REMAP-CAP, shock-dependent course, 2020
 
NCT02735707
RCTcorticosteroidsstandard of careCOVID-19 severe or criticallysome concern
152/108 inconclusive
    no demonstrated benefit a
Jianfeng, 2020OBScorticosteroidsstandard of careCOVID-19 severe or criticallyserious
-/- safety concern
  • statistically significant 1.8-fold increase in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
  • statistically significant 2.0-fold increase in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
Raef, 2020OBScorticosteroidsstandard of careCOVID-19 severe or criticallycritical
-/- suggested
  • suggested 55 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
Lu, 2020OBScorticosteroidscontrolCOVID-19 severe or criticallyserious
151/93 inconclusive
    no demonstrated benefit a

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);